Real-life survival with cabazitaxel shorter in FUJI vs TROPIC, PROSELICA
18 Nov 2019
bởiStephen Padilla
Treatment with cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) results in a slightly lower median overall survival (OS) at 18 months as compared with that in the pivotal clinical trial, owing to the presence of features of poor prognosis at baseline and use of cabazitaxel in third line or beyond in 82 percent of patients, according to the FUJI study.
Real-life survival with cabazitaxel shorter in FUJI vs TROPIC, PROSELICA
18 Nov 2019